C07D239/56

ELECTROPLATING COMPOSITION AND ELECTROPLATING METHOD
20200123671 · 2020-04-23 ·

The present invention relates to a electroplating composition and an electroplating method using the same. The electroplating composition of the present invention comprising a first leveling agent and a second leveling agent, wherein the first leveling agent and the second leveling agent each, independently, comprise a compound represented by Chemical Formula 1 below:

##STR00001##

HETEROCYCLIC COMPOUND AND COMPOSITION CONTAINING SAME
20200085051 · 2020-03-19 ·

A heterocyclic compound is represented by formula (I):

##STR00001##

in which R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms, n is 0, R.sup.3 represents a C1-C6 chain hydrocarbon group optionally having one or more substituents selected from Group B, q is 0, Het represents a group represented by the formulae Het 1 or Het 2, A.sup.1 represents a nitrogen atom, and Q.sup.2 represents an oxygen atom. The compound has excellent efficacy for controlling harmful arthropods. A composition is provided which contains the compound of formula (I) and one or more additional ingredients.

MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS AND METHODS OF TREATMENT USING SAME

Small molecule inhibitors are claimed that selectively target the hemopexin domain of matrix metalloproteinase 9 (MMP-9) and do not inhibit the protease's catalytic functions. A method of treating cancer in a patient in need thereof with the compounds of the invention is also claimed.

MATRIX METALLOPROTEINASE-9 HEMOPEXIN DOMAIN INHIBITORS AND METHODS OF TREATMENT USING SAME

Small molecule inhibitors are claimed that selectively target the hemopexin domain of matrix metalloproteinase 9 (MMP-9) and do not inhibit the protease's catalytic functions. A method of treating cancer in a patient in need thereof with the compounds of the invention is also claimed.

Bromodomain inhibitors
11884680 · 2024-01-30 · ·

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

Bromodomain inhibitors
11884680 · 2024-01-30 · ·

The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase

The present disclosure discloses compounds capable of modulating the activity of -amino--carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD.sup.+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase

The present disclosure discloses compounds capable of modulating the activity of -amino--carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD.sup.+ biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

2-pyrimidone analogs as potent antiviral agents against Alphaviruses

The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

PRODRUGS OF NH-ACIDIC COMPOUNDS

The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.